Your browser doesn't support javascript.
loading
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.
Nadeu, Ferran; Royo, Romina; Massoni-Badosa, Ramon; Playa-Albinyana, Heribert; Garcia-Torre, Beatriz; Duran-Ferrer, Martí; Dawson, Kevin J; Kulis, Marta; Diaz-Navarro, Ander; Villamor, Neus; Melero, Juan L; Chapaprieta, Vicente; Dueso-Barroso, Ana; Delgado, Julio; Moia, Riccardo; Ruiz-Gil, Sara; Marchese, Domenica; Giró, Ariadna; Verdaguer-Dot, Núria; Romo, Mónica; Clot, Guillem; Rozman, Maria; Frigola, Gerard; Rivas-Delgado, Alfredo; Baumann, Tycho; Alcoceba, Miguel; González, Marcos; Climent, Fina; Abrisqueta, Pau; Castellví, Josep; Bosch, Francesc; Aymerich, Marta; Enjuanes, Anna; Ruiz-Gaspà, Sílvia; López-Guillermo, Armando; Jares, Pedro; Beà, Sílvia; Capella-Gutierrez, Salvador; Gelpí, Josep Ll; López-Bigas, Núria; Torrents, David; Campbell, Peter J; Gut, Ivo; Rossi, Davide; Gaidano, Gianluca; Puente, Xose S; Garcia-Roves, Pablo M; Colomer, Dolors; Heyn, Holger; Maura, Francesco.
Afiliação
  • Nadeu F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. nadeu@recerca.clinic.cat.
  • Royo R; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. nadeu@recerca.clinic.cat.
  • Massoni-Badosa R; Barcelona Supercomputing Center (BSC), Barcelona, Spain.
  • Playa-Albinyana H; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Garcia-Torre B; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Duran-Ferrer M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Dawson KJ; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Kulis M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Diaz-Navarro A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Villamor N; Wellcome Sanger Institute, Hinxton, UK.
  • Melero JL; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Chapaprieta V; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Dueso-Barroso A; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.
  • Delgado J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Moia R; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Ruiz-Gil S; Hospital Clínic of Barcelona, Barcelona, Spain.
  • Marchese D; Omniscope, Barcelona, Spain.
  • Giró A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Verdaguer-Dot N; Barcelona Supercomputing Center (BSC), Barcelona, Spain.
  • Romo M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Clot G; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Rozman M; Hospital Clínic of Barcelona, Barcelona, Spain.
  • Frigola G; Universitat de Barcelona, Barcelona, Spain.
  • Rivas-Delgado A; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Baumann T; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Alcoceba M; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • González M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Climent F; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Abrisqueta P; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Castellví J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Bosch F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Aymerich M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Enjuanes A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Ruiz-Gaspà S; Hospital Clínic of Barcelona, Barcelona, Spain.
  • López-Guillermo A; Hospital Clínic of Barcelona, Barcelona, Spain.
  • Jares P; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Beà S; Hospital Clínic of Barcelona, Barcelona, Spain.
  • Capella-Gutierrez S; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Gelpí JL; Hospital Clínic of Barcelona, Barcelona, Spain.
  • López-Bigas N; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Torrents D; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Campbell PJ; Biología Molecular e Histocompatibilidad, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Gut I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Rossi D; Biología Molecular e Histocompatibilidad, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Gaidano G; Hospital Universitari de Bellvitge-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Puente XS; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Garcia-Roves PM; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Colomer D; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Heyn H; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Maura F; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Nat Med ; 28(8): 1662-1671, 2022 08.
Article em En | MEDLINE | ID: mdl-35953718
ABSTRACT
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high-B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Linfoma Difuso de Grandes Células B Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Linfoma Difuso de Grandes Células B Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article